BIOCRYST PHARMACEUTICALS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $3.20 per share for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-27.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2017-02-27
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2015-03-31 was $11.83, a 9.64% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2014-03-31 was $10.79, a 665.25% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2013-03-31 was $1.41.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2016 was $3.20, a 72.22% decline from fiscal 2015.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2015 was $11.52, a 4.82% increase from fiscal 2014.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2014 was $10.99, a 260.33% increase from fiscal 2013.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2013 was $3.05, a 34.41% decline from fiscal 2012.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2016-12-31 | $3.20 10-K · filed 2017-02-27 | |||
| 2015-12-31 | $11.52 10-K · filed 2017-02-27 | |||
| 2015-09-30 | $11.99 10-Q · filed 2015-11-06 | |||
| 2015-06-30 | $11.98 10-Q · filed 2015-08-07 | |||
| 2015-03-31 | $11.83 10-Q · filed 2015-05-08 | |||
| 2014-12-31 | $10.99 10-K · filed 2017-02-27 | |||
| 2014-09-30 | $10.78 10-Q · filed 2014-11-07 | |||
| 2014-06-30 | $10.28 10-Q · filed 2014-08-08 | |||
| 2014-03-31 | $10.79 10-Q · filed 2014-05-09 | |||
| 2013-12-31 | $3.05 10-K · filed 2016-02-26 | |||
| 2013-09-30 | $3.02 10-Q · filed 2013-11-08 | |||
| 2013-06-30 | $1.43 10-Q · filed 2013-08-08 | |||
| 2013-03-31 | $1.41 10-Q · filed 2013-05-09 | |||
| 2012-12-31 | $4.65 10-K · filed 2015-03-02 | |||
| 2012-09-30 | $4.65 10-Q · filed 2012-11-08 | |||
| 2012-06-30 | $4.66 10-Q · filed 2012-08-08 | |||
| 2011-12-31 | $3.97 10-K · filed 2014-03-10 | |||
| 2010-12-31 | $6.68 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |